Actively Recruiting
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Led by Qinghai Red Cross Hospital · Updated on 2024-03-29
230
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival.
CONDITIONS
Official Title
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Eastern Cooperative Oncology Group performance status of 0-3
- Stage III or IV inoperable or metastatic gastric, esophageal, hepato-pancreaticobiliary, and lung cancer confirmed by histology or cytology
- Receiving palliative systemic chemotherapy, regardless of first-line or second-line treatment
- Expected survival of at least 3 months
- Able to take oral medications without dietary restrictions
- Willing to adhere to treatment and follow-up and sign informed consent form
You will not qualify if you...
- Weight changes caused by factors like edema or ascites
- Mental disorders or current use of antipsychotic or antidepressant drugs
- History of central nervous system disorders such as brain metastasis or epilepsy
- Use of sedative medications, long-term hormonal therapy, chronic alcoholism, or substance dependence
- Contraindications for olanzapine use
- History of clozapine-induced agranulocytosis
- Uncontrolled diabetes mellitus or seizure disorders
- Pregnant or nursing women
- Participation in another interventional or observational clinical trial or survival follow-up phase
- Any condition that could harm the participant or interfere with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qinghai Red Cross Hospital
Xining, Qinghai, China, 810000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here